A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

Abstract:

:The potential for iloperidone, a D2/5-HT2A antipsychotic, to affect the heart rate-corrected QT interval (QTc) was assessed in the absence and presence of metabolic inhibitors in a randomized, open-label, multicenter study. QT interval prolongation by medications, including both conventional and atypical antipsychotic drugs, can predispose patients to cardiac arrhythmias and result in sudden death. Adults with schizophrenia or schizoaffective disorder and normal electrocardiograms at baseline (N = 188) were randomized 1:1:1:1:1 to iloperidone, 8 mg twice daily (BID), 12 mg BID, 24 mg once daily (QD); quetiapine, 375 mg BID; or ziprasidone, 80 mg BID during period 1 (no metabolic inhibitors present). Iloperidone BID produced mean changes in QTc Fridericia correction (QTcF) interval (8.5-9.0 milliseconds [ms]) similar to those produced by ziprasidone (9.6 ms) and higher than those produced by quetiapine (1.3 ms). Iloperidone, 24 mg QD, produced a mean QTcF change of 15.4 ms. Coadministration of metabolic inhibitors with iloperidone during periods 2 (paroxetine) and 3 (paroxetine and ketoconazole) resulted in greater increases in the QTc interval. Increased QTc was observed in individuals with specific cytochrome P450 2D6 polymorphisms. Up to 10% of patients on iloperidone experienced QTc intervals of 60 ms or longer in the presence of metabolic inhibition and QD dosing. However, no patients experienced QTc changes of clinical concern (QTc ≥ 500 ms). The most common adverse events with iloperidone were headache, anxiety, and dyspepsia. The only cardiovascular adverse events with iloperidone were non-concentration-dependent tachycardia that was mild in most patients and did not lead to further sequelae. Pharmacogenetics and recommendations are discussed.

journal_name

J Clin Psychopharmacol

authors

Potkin SG,Preskorn S,Hochfeld M,Meng X

doi

10.1097/JCP.0b013e31827c0314

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

3-10

issue

1

eissn

0271-0749

issn

1533-712X

journal_volume

33

pub_type

杂志文章,多中心研究,随机对照试验
  • Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

    abstract:OBJECTIVE:Medication algorithms have been proposed as effective means to offer optimal treatment and improved outcome for patients with severe mental illness. This single-center prospective study compared the efficacy and effects on treatment prescriptions of an algorithm-guided treatment regimen with treatment as usua...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3181ac4839

    authors: Bauer M,Pfennig A,Linden M,Smolka MN,Neu P,Adli M

    更新日期:2009-08-01 00:00:00

  • Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study.

    abstract:BACKGROUND:Depression, the leading cause of nonfatal disease burden, has a strong correlation with suicide and affects approximately 7% of the general elderly population. Adverse drug reactions in older patients are particularly important because of reduced drug metabolism, polypharmacy, drug-drug interactions, and dru...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001059

    authors: Kim S,Ko YJ,Park K,Yang BR,Kim MS,Park BJ

    更新日期:2019-07-01 00:00:00

  • Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.

    abstract::Cognitive dysfunction in patients with schizophrenia is a strong correlate of poor outcome than any other symptom domain. To have greater knowledge about the effects of antipsychotics on cognitive function, subjects of this study were healthy volunteers who had no confounding variables typically found in patients with...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e318272d10c

    authors: Chung YC,Park TW,Yang JC,Huang GB,Zhao T,Oh KY,Kim MG

    更新日期:2012-12-01 00:00:00

  • Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.

    abstract::Some of the selective serotonin reuptake inhibitors (SSRI)-induced motor side effects are mediated by stimulating 5-HT2 receptors in the basal ganglia, probably because serotonin inhibits the subsequent neuronal dopamine release. We hypothesized that nefazodone, a serotonin 2 antagonist/reuptake inhibitor (SARI) that ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000088908.24613.db

    authors: Avila A,Cardona X,Martin-Baranera M,Maho P,Sastre F,Bello J

    更新日期:2003-10-01 00:00:00

  • Characterizing anticholinergic abuse in community mental health.

    abstract::To identify factors associated with anticholinergic abuse in patients taking antipsychotics and anticholinergics and to document the extent of extrapyramidal side effects in anticholinergic abusers, 21 anticholinergic abusers were matched with 21 controls without a history of anticholinergic abuse for diagnosis and an...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Wells BG,Marken PA,Rickman LA,Brown CS,Hamann G,Grimmig J

    更新日期:1989-12-01 00:00:00

  • DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers.

    abstract::Hyperprolactinemia mediated by antagonism of dopaminergic neurotransmission in the pituitary gland is a common adverse effect of antipsychotics. Recent studies have suggested that polymorphisms of dopamine receptors can affect the therapeutic response to antipsychotics. Thus, our aim was to evaluate whether 2 such pol...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31822cfff2

    authors: López-Rodríguez R,Román M,Novalbos J,Pelegrina ML,Ochoa D,Abad-Santos F

    更新日期:2011-10-01 00:00:00

  • Use and safety of antipsychotics in behavioral disorders in elderly people with dementia.

    abstract::In recent years, the use of antipsychotics has been widely debated for reasons concerning their safety in elderly patients affected with dementia. To update the use of antipsychotics in elderly demented people, a MEDLINE search was conducted using the following terms: elderly, conventional and atypical antipsychotics,...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0b013e3182a6096e

    authors: Gareri P,De Fazio P,Manfredi VG,De Sarro G

    更新日期:2014-02-01 00:00:00

  • Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

    abstract:INTRODUCTION:One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metabolizers (PMs) or extensive metabolizers (EMs); the metabolism...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181acc4dd

    authors: Nichols AI,Lobello K,Guico-Pabia CJ,Paul J,Preskorn SH

    更新日期:2009-08-01 00:00:00

  • Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

    abstract::This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia. Data were pooled from 3 prospective multicenter studies, each with 6-week stabilization followed by 46-week double-blind maintenance phases. Patients were randomized to iloperidone 4 to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318169cca7

    authors: Kane JM,Lauriello J,Laska E,Di Marino M,Wolfgang CD

    更新日期:2008-04-01 00:00:00

  • Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

    abstract::The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose m...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000416

    authors: McIntyre RS,Gorwood P,Thase ME,Liss C,Desai D,Chen J,Bauer M

    更新日期:2015-12-01 00:00:00

  • Rate of increase of plasma lorazepam concentrations: absence of influence upon subjective and objective effects.

    abstract::This study was designed to investigate the relationship between subjective and objective effects of a benzodiazepine on the one hand, and the rate of increase of plasma concentration on the other. The pharmacokinetic variables of 10 normal volunteers were calculated following a single intravenous bolus injection of 1 ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Boulenger JP,Smokcum R,Lader M

    更新日期:1984-02-01 00:00:00

  • Pharmacokinetics of valproate and carbamazepine.

    abstract::Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use. Much of the information has been gained through their use as successful antiepileptic medications. As these agents begin to play an increasing role as mood-s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199202001-00010

    authors: Wilder BJ

    更新日期:1992-02-01 00:00:00

  • Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter?

    abstract:OBJECTIVES:It is unknown to which degree the effect of antidepressant drugs are related to baseline degree of depression, dose level, patient's age, or type of questionnaire used. We explored this for paroxetine. METHODS:We used placebo-controlled published and unpublished randomized, double-blind, clinical trials of ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318210bac1

    authors: Klemp M,Tvete IF,Gåsemyr J,Natvig B,Aursnes I

    更新日期:2011-04-01 00:00:00

  • Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics.

    abstract::Consensus guidelines which are applicable in New Zealand and worldwide recommend that the duration of exposure to antipsychotics not exceed 12 weeks, unless justified for mental illnesses like schizophrenia and severe psychotic symptoms which require longer treatment. There has been limited information on time-to-firs...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000597

    authors: Ndukwe HC,Nishtala PS

    更新日期:2016-12-01 00:00:00

  • Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

    abstract::Although many patients with major depressive disorder (MDD) complain of neurocognitive impairment, the effects of antidepressant medications on neurocognitive functions remain unclear. This study compares neurocognitive effects of tianeptine and escitalopram in MDD. Patients with MDD (N = 164) were randomly assigned i...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0000000000000072

    authors: Jeon HJ,Woo JM,Lee SH,Kim EJ,Chung S,Ha JH,Fava M,Mischoulon D,Kim JH,Heo JY,Yu BH

    更新日期:2014-04-01 00:00:00

  • Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.

    abstract::Serotonin 2C and 2A receptor (5-HT2C and 5-HT2A) antagonisms are hypothesized to play a role in the metabolic adverse effects induced by olanzapine and clozapine. Associations between polymorphisms in 5-HT2C and 5-HT2A receptor coding genes, HTR2C and HTR2A, with antipsychotic-induced weight gain have been reported. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31819302c3

    authors: Gunes A,Melkersson KI,Scordo MG,Dahl ML

    更新日期:2009-02-01 00:00:00

  • Haloperidol half-life after chronic dosing.

    abstract::In normal subjects after a single oral dose, haloperidol half-life has been reported to range 14.5-36.7 hours (or up to 1.5 days). After chronic administration, half-lives of up to 21 days have been reported. The objective of this study was to evaluate specific factors that might account for differences in haloperidol...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000145340.53417.ca

    authors: de Leon J,Diaz FJ,Wedlund P,Josiassen RC,Cooper TB,Simpson GM

    更新日期:2004-12-01 00:00:00

  • Effect of fluvoxamine on panic disorder.

    abstract::Several reports suggest that selective serotonin reuptake blockers are helpful in the treatment of panic disorder. The aim of the study was to compare fluvoxamine with placebo in 50 panic disorder patients by using an 8-week, double-blind, parallel-groups design. Weekly assessment included a panic attack diary (freque...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Hoehn-Saric R,McLeod DR,Hipsley PA

    更新日期:1993-10-01 00:00:00

  • Treatment-resistant catatonic stupor and combined lithium-neuroleptic therapy: a case report.

    abstract::A case of treatment-resistant catatonic stupor responding to combined lithium-neuroleptic medications is described. As there are no reports in the literature of combined lithium-neuroleptic medications being effective for this potentially life-threatening disorder, the course of recovery is detailed and the risks and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Climo LH

    更新日期:1985-06-01 00:00:00

  • Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

    abstract::Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focu...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/JCP.0b013e3181dbfd04

    authors: Warden D,Trivedi MH,Wisniewski SR,Kurian B,Zisook S,Kornstein SG,Friedman ES,Miyahara S,Leuchter AF,Fava M,Rush AJ

    更新日期:2010-06-01 00:00:00

  • The evolution of treatment resistance: biologic implications.

    abstract::The evolution of resistance of positive symptoms to antipsychotic therapy may represent a valuable means of subtyping schizophrenia. In contrast, resistance of negative symptoms and cognitive function to antipsychotic agents seems to be present from the first episode of psychotic symptoms and does not evolve over time...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199804001-00003

    authors: Meltzer HY,Lee M,Cola P

    更新日期:1998-04-01 00:00:00

  • Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.

    abstract::In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was moni...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200004000-00014

    authors: Ulrich S,Neuhof S,Braun V,Danos P,Pester U,Hoy L

    更新日期:2000-04-01 00:00:00

  • Comparative abuse liability of intravenously administered remifentanil and fentanyl.

    abstract::Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 mi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200012000-00002

    authors: Baylon GJ,Kaplan HL,Somer G,Busto UE,Sellers EM

    更新日期:2000-12-01 00:00:00

  • Prediction of individual dosage of nortriptyline in depressed elderly outpatients.

    abstract::Individual daily dosages of nortriptyline (NT) can be predicted from administration of a 50-mg or 100-mg single test dose, with a determination of the plasma level 24 hours later. Because the 50-mg or 100-mg test dose used in previous studies may cause unmanageable acute side effects in elderly patients, a 25-mg NT te...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Schneider LS,Cooper TB,Staples FR,Sloane RB

    更新日期:1987-10-01 00:00:00

  • Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.

    abstract::The objective of this study was twofold: (1) to describe the effects of risperidone on the quantitative electroencephalogram (EEG) in schizophrenic patients and (2) to explore the relationships between EEG changes and clinical improvement. The subjects were nine male schizophrenic patients participating in a placebo-c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Czobor P,Volavka J

    更新日期:1993-10-01 00:00:00

  • Clozapine Use in a Cohort of First-Episode Psychosis.

    abstract:PURPOSE/BACKGROUND:For approximately one third of individuals treated for psychosis or schizophrenia, antipsychotic medications will have little or no therapeutic benefit. Clozapine remains the sole medication approved for treatment-resistant schizophrenia, and studies have demonstrated its superior efficacy in reducin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000734

    authors: Doyle R,Behan C,OʼKeeffe D,Masterson S,Kinsella A,Kelly A,Sheridan A,Keating D,Hynes C,Madigan K,Lawlor E,Clarke M

    更新日期:2017-10-01 00:00:00

  • Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

    abstract::On the basis of a previous report suggesting the effectiveness of the beta-adrenoceptor/5-HT1A antagonist pindolol to accelerate the antidepressant effect of a selective serotonin reuptake inhibitor (SSRI) and to produce a therapeutic effect in drug-resistant depressed patients, these open studies were undertaken to f...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199506000-00011

    authors: Blier P,Bergeron R

    更新日期:1995-06-01 00:00:00

  • Predictors for starting depot administration of risperidone in chronic users of antipsychotics.

    abstract:BACKGROUND:Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparison...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31818a6d10

    authors: Vehof J,Postma MJ,Bruggeman R,De Jong-Van Den Berg LT,Van Den Berg PB,Stolk RP,Burger H

    更新日期:2008-12-01 00:00:00

  • The pharmacologic treatment of neuroleptic-induced akathisia.

    abstract::Akathisia is a frequent and distressing side effect of neuroleptic medications. The literature regarding the pharmacologic treatment of acute neuroleptic-induced akathisia is critically reviewed, including nine reports of the use of anticholinergic agents, 15 of the use of beta-blocking agents, and six of the use of b...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00004714-199002000-00003

    authors: Fleischhacker WW,Roth SD,Kane JM

    更新日期:1990-02-01 00:00:00

  • Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment.

    abstract::Two experiments examined the effects of methylphenidate in male and female patients enrolled in an outpatient treatment program for primary cocaine dependence. The first study was a component of a double-blind efficacy trial wherein 57 patients were first tested in a human laboratory for their initial responsiveness t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200002000-00011

    authors: Roache JD,Grabowski J,Schmitz JM,Creson DL,Rhoades HM

    更新日期:2000-02-01 00:00:00